Classification
- Anatomical main groupVVarious
- Therapeutic subgroupV03
- Pharmacological subgroupV03A
- Chemical subgroupV03AF
- Chemical substanceV03AF07Rasburicase
Where it is registered
Each register with its number of medicines and a few of them.
Loading your page…
Each register with its number of medicines and a few of them.
Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.
SFDA · 2 medicines · Historical list
FDA · 2 medicines
EMA · 1 medicine
AIFA · 1 medicine
CBG-MEB · 1 medicine
PHARMAC · 1 medicine
HSA · 1 medicine
Every register, a page at a time. Strengths and packs are on each medicine’s page.
17 results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Elitek | United States | 1.5MG/VIAL | vial | Marketed | Sanofi Synthelabo |
| Elitek | United States | 7.5MG | For Injection | Marketed | Sanofi-Aventis U.S. LLC |
| Fasturtec | European Union | Authorised | Sanofi Winthrop Industrie | ||
| Fasturtec 1,5 MG/ML Polvo y Disolvente Para Concentrado Para Solucion Para Perfusion | Spain | 1,5 mg | polvo y disolvente para concentrado para solución para perfusión | Marketed | Sanofi Winthrop Industrie |
| Fasturtec | Italy | Polvere e solvente per soluzione per infusione endovenosa | Authorised | Sanofi Winthrop Industrie | |
| Fasturtec 1,5 mg/ml poeder en oplosmiddel voor concentraat voor oplossing voor infusie | Netherlands | Poeder en oplosmiddel voor concentraat voor oplossing voor infusie | Authorised | Sanofi Winthrop Industrie | |
| Fasturtec 1,5 MG/ML Polvo y Disolvente Para Concentrado Para Solucion Para Perfusion | Spain | 7,5 mg | polvo y disolvente para concentrado para solución para perfusión | Authorised | Sanofi Winthrop Industrie |
| Fasturtec | Canada | 1.5 MG / VIAL | Powder For Solution | Marketed | Sanofi-Aventis Canada INC |
| Fasturtec | Brazil | Authorised | Sanofi Medley Farmacêutica Ltda. | ||
| FASTURTEC POWDER FOR SOLUTION FOR INFUSION 1.5 mg/vial | Singapore | 1.5 mg/vial | injection, powder, for solution | Authorised | Sanofi-Aventis Singapore Pte. LTD. |
| Fasturtec | Croatia | Marketed | |||
| Any | New Zealand | Inj 1.5 mg vial | Funded | ||
| Fasturtec | Saudi Arabia | Authorised | sanofi S.P.A | ||
| Fasturtec | Saudi Arabia | Authorised | sanofi S.P.A | ||
| Fasturtec | Brazil | Cancelled | Sanofi - Synthelabo Farmacêutica Ltda | ||
| Fasturtec | Canada | 7.5 MG / VIAL | Powder For Solution | Cancelled | Sanofi-Aventis Canada INC |
| Fasturtec | Brazil | Cancelled | Sanofi-Aventis Farmacêutica Ltda |
The same brand on several registers.
The companies holding its medicines, the most first.
How the registers write it, in their own languages.
Compiled by Prognia from the public medicine registers of AEMPS, AIFA, Anvisa, CBG-MEB, EMA, FDA, HALMED, Health Canada, HSA, PHARMAC and SFDA. Each medicine’s page names its own source, licence and attribution.
Report an error or request removalCorrections from a register or a company are welcome.
For reference and learning, not treatment advice. Always check the official product information.